Literature DB >> 21619555

Antimicrobial resistance status and prevalence rates of extended spectrum beta-lactamase (ESBL) producers isolated from a mixed human population.

Ruth A Afunwa1, Damian C Odimegwu, Romanus I Iroha, Charles O Esimone.   

Abstract

Owing to the increasing epidemiological and therapeutic challenges associated with infections due to ESBL producers, ESBL prevalence rate among some bacteria isolates from healthy and non-healthy human population in a metropolitan Nigerian setting was evaluated. A total of one hundred and forty-five (145) bacteria strains were isolated from a total of four hundred and sixty (460) samples collected from urine, wound, throat and anal swabs of 220 healthy volunteers in the community and from 240 patients in 2 secondary and 2 tertiary hospitals (altogether, 4) in Enugu metropolis. The presumptive confirmatory test used for ESBL detection was the Double Disc Synergy Test (DDST) method. Conjugation and plasmid curing studies were also done for resistance factor determination. Of the 145 isolates, 20 were ESBL producers with 35% of these ESBL producers being of community origin and 65% from hospitals. This translates to 4.8% and 9% incidences (comparably higher than established prevalence of 4.4% and 7.5 respectively) for community and hospital infections respectively. The ESBL isolates showed high resistance to tetracycline, gentamicin, pefloxacin, ceftriaxone, cefuroxime, ciprofloxacin and Augmentin(®) (Amoxicilin and clavulanic acid combination). Conjugation studies for Resistance plasmid transfer showed non-transference of resistance determinants between the ESBL transconjugants and recipient strains. Correspondingly, the plasmid curing studies revealed that the acridine orange could not effect a cure on the isolates as they still retained high resistance to the antibiotics after the treatment. This study confirms the growing incidences/pool of ESBL strains in Nigeria and call for widespread and continuous monitoring towards an effective management of the potential therapeutic hurdle posed by this trend.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21619555      PMCID: PMC4362596          DOI: 10.17305/bjbms.2011.2588

Source DB:  PubMed          Journal:  Bosn J Basic Med Sci        ISSN: 1512-8601            Impact factor:   3.363


  22 in total

Review 1.  The CTX-M beta-lactamase pandemic.

Authors:  Rafael Cantón; Teresa M Coque
Journal:  Curr Opin Microbiol       Date:  2006-08-30       Impact factor: 7.934

2.  Dissemination of extended-spectrum beta-lactamase-producing bacteria: the food-borne outbreak lesson.

Authors:  S Lavilla; J J González-López; E Miró; A Domínguez; M Llagostera; R M Bartolomé; B Mirelis; F Navarro; G Prats
Journal:  J Antimicrob Chemother       Date:  2008-03-12       Impact factor: 5.790

Review 3.  Drug-resistant Salmonella in the United States: an epidemiologic perspective.

Authors:  M L Cohen; R V Tauxe
Journal:  Science       Date:  1986-11-21       Impact factor: 47.728

Review 4.  A functional classification scheme for beta-lactamases and its correlation with molecular structure.

Authors:  K Bush; G A Jacoby; A A Medeiros
Journal:  Antimicrob Agents Chemother       Date:  1995-06       Impact factor: 5.191

5.  Extended-spectrum beta-lactamase-producing Enterobacteriaceae strains in community-acquired bacteremia in Southern Israel.

Authors:  Abraham Borer; Jacob Gilad; Galia Menashe; Nechama Peled; Klaris Riesenberg; Francisc Schlaeffer
Journal:  Med Sci Monit       Date:  2002-01

6.  In vitro susceptibilities of aerobic and facultatively anaerobic Gram-negative bacilli isolated from patients with intra-abdominal infections worldwide: 2004 results from SMART (Study for Monitoring Antimicrobial Resistance Trends).

Authors:  Flávia Rossi; Fernando Baquero; Po-Ren Hsueh; David L Paterson; Grant V Bochicchio; Theresa A Snyder; Vilas Satishchandran; Kathleen McCarroll; Mark J DiNubile; Joseph W Chow
Journal:  J Antimicrob Chemother       Date:  2006-05-22       Impact factor: 5.790

7.  Antibiotic therapy for Klebsiella pneumoniae bacteremia: implications of production of extended-spectrum beta-lactamases.

Authors:  David L Paterson; Wen-Chien Ko; Anne Von Gottberg; Sunita Mohapatra; Jose Maria Casellas; Herman Goossens; Lutfiye Mulazimoglu; Gordon Trenholme; Keith P Klugman; Robert A Bonomo; Louis B Rice; Marilyn M Wagener; Joseph G McCormack; Victor L Yu
Journal:  Clin Infect Dis       Date:  2004-06-08       Impact factor: 9.079

8.  Utilization of antimicrobial agents with and without prescription by out-patients in selected pharmacies in South-eastern Nigeria.

Authors:  Charles Okey Esimone; Chukwuemeka Sylvester Nworu; Obinna Patrick Udeogaranya
Journal:  Pharm World Sci       Date:  2007-04-27

Review 9.  [Current orientation of antibiotic treatment in neonatal bacterial infection].

Authors:  P Bégué
Journal:  Bull Soc Pathol Exot       Date:  1991

10.  Risk factors for colonization with extended-spectrum beta-lactamase-producing bacteria and intensive care unit admission.

Authors:  Anthony D Harris; Jessina C McGregor; Judith A Johnson; Sandra M Strauss; Anita C Moore; Harold C Standiford; Joan N Hebden; J Glenn Morris
Journal:  Emerg Infect Dis       Date:  2007-08       Impact factor: 6.883

View more
  8 in total

1.  Antibiotic resistance and extended spectrum beta-lactamases: Types, epidemiology and treatment.

Authors:  Sibhghatulla Shaikh; Jamale Fatima; Shazi Shakil; Syed Mohd Danish Rizvi; Mohammad Amjad Kamal
Journal:  Saudi J Biol Sci       Date:  2014-08-17       Impact factor: 4.219

Review 2.  ESBL-producing Enterobacteriaceae in Africa - a non-systematic literature review of research published 2008-2012.

Authors:  Viktor Storberg
Journal:  Infect Ecol Epidemiol       Date:  2014-03-13

3.  High prevalence of extended-spectrum ß-lactamase producing enterobacteriaceae among clinical isolates in Burkina Faso.

Authors:  Abdoul-Salam Ouedraogo; Mahamadou Sanou; Aimée Kissou; Soufiane Sanou; Hermann Solaré; Firmin Kaboré; Armel Poda; Salim Aberkane; Nicolas Bouzinbi; Idrissa Sano; Boubacar Nacro; Lassana Sangaré; Christian Carrière; Dominique Decré; Rasmata Ouégraogo; Hélène Jean-Pierre; Sylvain Godreuil
Journal:  BMC Infect Dis       Date:  2016-07-11       Impact factor: 3.090

4.  Extended-spectrum beta-lactamase- and carbapenemase-producing Enterobacteriaceae among Ethiopian children.

Authors:  Melese Hailu Legese; Gebru Mulugeta Weldearegay; Daniel Asrat
Journal:  Infect Drug Resist       Date:  2017-01-25       Impact factor: 4.003

5.  Multi-antibiotic resistant extended-spectrum beta-lactamase producing bacteria pose a challenge to the effective treatment of wound and skin infections.

Authors:  Angus Nnamdi Oli; Dennis Emeka Eze; Thaddeus Harrison Gugu; Ifeanyi Ezeobi; Ukamaka Nwakaku Maduagwu; Chibueze Peter Ihekwereme
Journal:  Pan Afr Med J       Date:  2017-05-30

6.  Bacteria Producing Extended Spectrum β-lactamases (ESBLs) in Hospitalized Patients: Prevalence, Antimicrobial Resistance Pattern and its Main Determinants.

Authors:  Mehdi Yousefipour; Mehrnaz Rasoulinejad; Azar Hadadi; Negin Esmailpour; Alireza Abdollahi; Sirous Jafari; Atieh Khorsand
Journal:  Iran J Pathol       Date:  2018-12-27

7.  High Emergence of ESBL-Producing E. coli Cystitis: Time to Get Smarter in Cyprus.

Authors:  Leon Cantas; Kaya Suer; Emrah Guler; Turgut Imir
Journal:  Front Microbiol       Date:  2016-01-13       Impact factor: 5.640

8.  Prevalence of Extended Spectrum β-Lactamase and Antimicrobial Susceptibility Pattern of Clinical Isolates of Pseudomonas from Patients of Khyber Pakhtunkhwa, Pakistan.

Authors:  Manzoor Ahmad; Mukhtiar Hassan; Anwar Khalid; Imran Tariq; Muhammad Hassham Hassan Bin Asad; Abdul Samad; Qaisar Mahmood; Ghulam Murtaza
Journal:  Biomed Res Int       Date:  2016-06-05       Impact factor: 3.411

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.